Organization
Texas Oncology PA
5 abstracts
Abstract
A unique model: Partnership between community oncology and pharma for clinical trial enrichment.Org: Texas Oncology, Mirati Therapeutics, Texas Oncology PA, Texas Oncology Tyler, Texas Oncology - Baylor Charles A. Sammons Cancer Center,
Abstract
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.Org: University of Calgary, Texas Oncology PA, Ipsen, Ontada, McMaster University and Juravinski Cancer Centre,
Abstract
Neurocognitive function outcomes in NRG/RTOG 0534, the SPPORT trial.Org: MD Anderson Cancer Center, University of Chicago, University of Miami Health System, Tom Baker Cancer Centre, Emory University, Atlanta, GA, USA,
Abstract
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Severance Hospital, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Research Institute,
Abstract
AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.Org: Fox Chase Cancer Center, O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Norton Cancer Institute, Texas Oncology PA, OHSU - Oregon Health and Science University,